BioSpace News Archive

Cellectis announced preliminary results from the BALLI-01 Phase 1 study of UCART22, its allogeneic CAR-T cell therapy candidate targeting CD22, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia, and preclinical data on TALGlobin01, its autologous cell therapy product candidate for homozygous SCD patients at the 63rd Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

Novartis announced Kymriah® demonstrated strong efficacy in high-risk patients with relapsed or refractory follicular lymphoma based on a subgroup analysis from an approximately 17-month median follow-up of the pivotal Phase II ELARA study.

AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, announced preliminary data from the ongoing open-label portion of a Phase 2 study assessing the safety and efficacy of posoleucel for the prevention of clinically significant infections and end-organ diseases from six potentially life-threatening viruses in high-risk patients following allogeneic hematopoietic cell transplantation.

To discuss the clinical data from the MaaT013 program and provide a corporate update, MaaT Pharma will host an investor webcast on Monday, December 13, 2021 at 6:00 pm CET/ 12:00 pm EST.

Vincerx Pharma, Inc. announced data on VIP152, the Company’s PTEFb/CDK9 inhibitor, in high-grade B-cell lymphoma, formerly referred to as double-hit lymphoma, and chronic lymphocytic leukemia, in two presentations at the 63rd American Society of Hematology Annual Meeting held December 11-14, 2021 in Atlanta GA.

Precision BioSciences, Inc., a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion 1 presented at the 63rd American Society of Hematology Annual Meeting.

Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced clinical data from an ongoing Phase 1 study of TT11X, an allogeneic “off the shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy being co-developed by Baylor College of Medicine and Tessa.

Four studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition highlight opportunities to better serve the needs of patients who have not fully benefited from recent advances in leukemia care and treatment.

Four studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition point to the transformative role immunotherapies are playing in the treatment of major blood cancers.

Kite, a Gilead Company, announced results from the primary analysis of ZUMA-7, a global Phase 3 study evaluating Yescarta® as a one-time infusion, in a head-to-head study against standard of care for adults with large B-cell lymphoma who relapsed or were refractory to first-line treatment.